Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?

ABSTRACT:

Objectives

Despite concerted efforts, Mycobacterium tuberculosis (M.tb), the pathogen that causes tuberculosis (TB), continues to be a burden on global health, regaining its dubious distinction in 2022 as the world's biggest infectious killer with global COVID-19 deaths steadily declining. The complex nature of M.tb, coupled with different pathogenic stages, has highlighted the need for the development of novel immunization approaches to combat this ancient infectious agent. Intensive efforts over the last couple of decades have identified alternative approaches to improve upon traditional vaccines that are based on killed pathogens, live attenuated agents, or subunit recombinant antigens formulated with adjuvants. Massive funding and rapid advances in RNA-based vaccines for immuni

SUBMITTER: Larsen SE 

PROVIDER: S-EPMC10033141 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature